金吾财讯 | 四环医药（00460）公告公布，近期，集团旗下渼颜空间生物科技（吉林）有限公司（“渼颜空间”）自主研发及生产的注射用聚己内酯微球面部填充剂（“PCL”）、注射用透明质酸钠复合溶液(FL)（“动能素”），已相继于香港获批上市。此次获批的注射用聚己内酯微球面部填充剂获批规格包括0.5mL╱支、1.0mL╱支、2.0mL╱支；注射用透明质酸钠复合溶液获批规格包括0.5mL╱支、1.0mL╱支、1.5mL╱支、2.0mL╱支、2.5mL╱支、3.0mL╱支、5mL╱盒（内含2支2.5mL╱支规格产品）。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.